Dr. Lal PathLabs Limited records growth of 17.7% in Q1 FY2016-17
New Delhi, India, July 29, 2016 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended June 30, 2016
Consolidated Performance Highlights: Q1FY2016-17 vs. Q1FY2015-16
· Operating Revenue increased by 17.7% Y-o-Y to Rs. 2228 million vs Rs 1893 million in the previous year. Underlying volume growth is 15%
· EBITDA increased by 22.7% Y-o-Y to Rs.604 million from Rs 492 million in the same quarter last year. Normalised EBITDA increased by 17.3% after adjusting for ESOP provisions in PY financials.
· EBITDA Margin was 27.1% for Q1 2016 vs 26% in Q1 2015
· Profit after Tax increased by 29.7% to Rs. 402 million from Rs 310 million; Margins of 18% vs 16.4% last year in Q1
Commenting on the results and performance, Dr. Arvind Lal, Chairman and Managing Director
said:
I am delighted to share the Q1 2016 financial and operating results of the Company which have shown a healthy growth of nearly 18%. I am pleased to inform that our persistent pursuit and efforts to grow our brand and provide better diagnostic services to a nation where there is an immense and urgent need for quality healthcare, has translated in us not only fulfilling our passion but has also generated positive results. Our continuous initiatives to innovate and expand have enabled us stay ahead on our growth curve, in a sector which we believe is highly dynamic and competitive
I am happy to announce that the business has grown in June Quarter 20 16 to a revenue of Rs 2228 mn. The PAT has grown to Rs 402 mn with a margin of 18%. The revenue growth was driven by 15% volume growth in Q1 2016. We are confident that with the support and commitment of our teams we will continue to deliver high quality services to our patients and drive growth and create significant value for all our stakeholders.
About Dr. Lal PathLabs Limited
Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
Dr. Lal PathLabs has built a national, “hub and spoke” network that includes its National Reference
Laboratory in New Delhi, 171 other clinical laboratories, 1,559 patient service centers and nearly
5,000 pickup points as of March 31, 2016. Their customers include individual patients, hospitals and
other healthcare providers and corporate customers.
Financial Overview (Consolidated)
Particulars
|
JQ'16
|
JQ'15
|
Gr %
|
Total Revenue
|
2,228.4
|
1,893.1
|
17.7%
|
Total Expenditure
|
1,624.3
|
1,378.5
|
17.8%
|
ESOP
|
-
|
22.5
| |
EBITDA
|
604.0
|
492.1
|
22.7%
|
Margins
|
27.1%
|
26.0%
| |
PBT
|
599.3
|
468.3
|
28.0%
|
Margins
|
26.9%
|
24.7%
| |
PAT
|
401.7
|
309.8
|
29.7
|